Fomina-Yadlin D, Kubicek S, Vetere A, et al. GW8510 increases insulin expression in pancreatic alpha cells through activation of p53 transcriptional activity. PLoS One. 2012;7(1):e28808. doi:10.1371/journal.pone.0028808
Derks S, Bass AJ. Mutational signatures in Helicobacter pylori-induced gastric cancer: lessons from new sequencing technologies. Gastroenterology. 2014;147(2):267-9. doi:10.1053/j.gastro.2014.06.019
Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30(5):413-21. doi:10.1038/nbt.2203
Tchaicha JH, Akbay EA, Altabef A, et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014;74(17):4676-84. doi:10.1158/0008-5472.CAN-13-3218
Janas MM, Wang E, Love T, et al. Reduced expression of ribosomal proteins relieves microRNA-mediated repression. Mol Cell. 2012;46(2):171-86. doi:10.1016/j.molcel.2012.04.008
Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705-12. doi:10.1182/blood-2014-06-582809
Brown-Endres L, Schoenfeld D, Tian F, et al. Expression of the p53 target CDIP correlates with sensitivity to TNFα-induced apoptosis in cancer cells. Cancer Res. 2012;72(9):2373-82. doi:10.1158/0008-5472.CAN-11-3369
Merlo P, Frost B, Peng S, Yang YJ, Park PJ, Feany M. p53 prevents neurodegeneration by regulating synaptic genes. Proc Natl Acad Sci U S A. 2014;111(50):18055-60. doi:10.1073/pnas.1419083111
Benassi B, Flavin R, Marchionni L, et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012;2(3):236-47. doi:10.1158/2159-8290.CD-11-0219
Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51):E5564-73. doi:10.1073/pnas.1419260111